| Identification | Back Directory | [Name]
1H-Benz[de]isoquinoline-1,3(2H)-dione, 2-(2,3-dihydro-1-methyl-2-oxo-1H-benzimidazol-5-yl)-6-(3-hydroxypropyl)- | [CAS]
2097610-30-3 | [Synonyms]
1H-Benz[de]isoquinoline-1,3(2H)-dione, 2-(2,3-dihydro-1-methyl-2-oxo-1H-benzimidazol-5-yl)-6-(3-hydroxypropyl)- | [Molecular Formula]
C23H19N3O4 | [MOL File]
2097610-30-3.mol | [Molecular Weight]
401.41 |
| Chemical Properties | Back Directory | [density ]
1.431±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 5mg/mL, clear (warmed) | [form ]
powder | [pka]
11.76±0.30(Predicted) | [color ]
white to light brown |
| Hazard Information | Back Directory | [Uses]
BAY-364 (BAY-299N) is an inhibitor of the second bromine domain in TAF1. BAY-364 inhibits the TAF1 of Kasumi-1 cells, CD34+ cells and K562 cells with IC50 values of 1.0 μM, 10.4 μM and 10.0 μM respectively[1]. | [Biological Activity]
BAY-364 (BAY-299N) is structurally similar to selective BRD1/TAF1 inhibitor BAY-299 and serves as inactive control. BAY-364 is inactive against BRD1 and exhibit moderate activity against TAF1 (3 μM). For full characterization details of the active probeplease visit the BAY-299 probe summary on the Structural Genomics Consortium (SGC) website.
BAY-299the active probeis available from Sigma. To learn more about and purchase BAY-299click here.
To learn about other SGC chemical probes for protein targetsvisit sigma.com/sgc | [References]
[1] Xu Y, et al. TAF1 plays a critical role in AML1-ETO driven leukemogenesis. Nat Commun. 2019 Oct 29;10(1):4925. DOI:10.1038/s41467-019-12735-z
[2] Garcia-Carpizo V, et al. Therapeutic potential of TAF1 bromodomains for cancer treatment[J]. bioRxiv, 2018: 394254. |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|